A retrospective study suggested Vistide significantly improved the lives of 70% of severely ill ME/XCFS patients.

A retrospective study suggested Vistide significantly improved the lives of 70% of severely ill ME/XCFS patients.

In a first for ME/CFS, at the HHV6 Conference in Paris Dr. Peterson reported a retrospective study indicated a little used anti-herpesvirus drug called Vistide significantly helped 70% of severely ill patients – with many able to return to work. With this unusually high success rate in this difficult to treat group Peterson called for multi-center studies to build on these results.

Click here to read the blog on the Simmaron Foundation website

Share This